NewcelX Offloads Mazindol Portfolio for $500K Upfront, Up to $55M in Milestones
NCEL sits 44% above its 52-week low of $1.83 on elevated volume (2.2× avg).
Summary
NewcelX signed a binding term sheet to sell its worldwide Mazindol portfolio, taking only $500K in attributed upfront value — just $30K of it cash, with the rest in shares equal to 9.4% of buyer REA's fully diluted equity after closing. The deal carries up to $55M in contingent milestones plus 2%-8% royalties on global net sales, so the real money depends on development and commercialization that may never happen. The cash component is negligible against a company that disclosed $710K in cash and a going concern warning in its September 6-K, so this does not solve the funding problem. It does strip out a legacy asset as management pivots to the cell-therapy pipeline, and the REA stake gives NewcelX a levered bet on the buyer's execution. Definitive documents and closing conditions still have to be satisfied before anything is final.
At the time of this announcement, NCEL was trading at $2.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $1.83 to $6.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.